A novel role for raloxifene nanomicelles in management of castrate resistant prostate cancer

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Taurin, Sebastien ^a   Nehoff, Hayley ^a   Van Aswegen, Thalita ^a   Rosengren, Rhonda J ^a   Greish, Khaled ^a,b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b Suez Canal University Faculty of Medicine   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

BETA TUBULIN; CASPASE 3; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN KINASE B; RALOXIFENE; STYRENE MALEIC ANHYDRIDE COPOLYMER; DNA; ESTROGEN RECEPTOR; MALEIC ACID DERIVATIVE; MICELLE; NANOPARTICLE; POLYSTYRENE DERIVATIVE; STYRENE-MALEIC ACID POLYMER;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CASTRATION RESISTANT PROSTATE CANCER; CELL COUNT; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXICITY; DNA SYNTHESIS; DRUG DOSAGE FORM COMPARISON; DRUG RELEASE; ENCAPSULATION; ENZYME ACTIVITY; ESTROGEN RESPONSIVE ELEMENT; HUMAN; HUMAN CELL; MALE; MICELLE; MOLECULAR WEIGHT; NANOENCAPSULATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TUMOR SPHEROID; UMBILICAL VEIN ENDOTHELIAL CELL; BIOSYNTHESIS; CELL CYCLE; CELL MOTION; CHEMISTRY; DRUG EFFECTS; IC50; METABOLISM; MULTICELLULAR SPHEROID; NECROSIS; PATHOLOGY; PH; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN SYNTHESIS; SECRETION (PROCESS); TUMOR CELL LINE; TUMOR INVASION;

APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DNA, NEOPLASM; HUMANS; HYDROGEN-ION CONCENTRATION; INHIBITORY CONCENTRATION 50; MALE; MALEATES; MATRIX METALLOPROTEINASE 9; MICELLES; NANOPARTICLES; NECROSIS; NEOPLASM INVASIVENESS; POLYSTYRENES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN BIOSYNTHESIS; RALOXIFENE; RECEPTORS, ESTROGEN; SPHEROIDS, CELLULAR;

EID: 84896837299     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/323594     Document Type: Article

References (66)

1. Walsh P. C., DeWeese T. L., Eisenberger M. A., Localized prostate cancer. The New England Journal of Medicine 2007 357 26 2696 2705 2-s2.0-37549020086 10.1056/NEJMcp0706784
2. Kelly K., Yin J. J., Prostate cancer and metastasis initiating stem cells. Cell Research 2008 18 5 528 537 2-s2.0-43049093781 10.1038/cr.2008.50
3. Attard G., Reid A. H. M., Olmos D., De Bono J. S., Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Research 2009 69 12 4937 4940 2-s2.0-67449119425 10.1158/0008-5472.CAN-08-4531
4. Pound C. R., Partin A. W., Eisenberger M. A., Chan D. W., Pearson J. D., Walsh P. C., Natural history of progression after PSA elevation following radical prostatectomy. Journal of the American Medical Association 1999 281 17 1591 1597 2-s2.0-0033526309 10.1001/jama.281.17.1591
5. Brawley O. W., Prostate cancer epidemiology in the United States. World Journal of Urology 2012 30 2 195 200 2-s2.0-84859439993 10.1007/s00345-012-0824- 2
6. Ho S. M., Lee M. T., Lam H. M., Leung Y. K., Estrogens and prostate cancer: etiology, mediators, prevention, and management. Endocrinology and Metabolism Clinics of North America 2011 40 3 591 614 2-s2.0-80052249325 10.1016/j.ecl.2011.05.002
7. Noble R. L., Production of Nb rat carcinoma of the dorsal prostate and response of estrogen-dependent transplants to sex hormones and tamoxifen. Cancer Research 1980 40 10 3547 3550 2-s2.0-0018932456
8. Ricke W. A., McPherson S. J., Bianco J. J., Cunha G. R., Wang Y., Risbridger G. P., Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling. The FASEB Journal 2008 22 5 1512 1520 2-s2.0-43249092379 10.1096/fj.07-9526com
9. Bosland M. C., Ford H., Horton L., Induction of high incidence of ductal prostate adenocarcinomas in NBL/Cr and Sprague-Dawley Hsd:SD rats treated with a combination of testosterone and estradiol-17 β or diethylstilbestrol. Carcinogenesis 1995 16 6 1311 1317 2-s2.0-0029020560
10. Leav I., Ho S. M., Ofner P., Merk F. B., Kwan P. W. L., Damassa D., Biochemical alterations in sex hormone-induced hyperplasia and dysplasia of the dorsolateral prostates of noble rats. Journal of the National Cancer Institute 1988 80 13 1045 1053 2-s2.0-0023788508
11. Yu M., Leav B. A., Leav I., Merk F. B., Wolfe H. J., Ho S.-M., Early alterations in ras protooncogene mRNA expression in testosterone and estradiol-17 β induced prostatic dysplasia of Noble rats. Laboratory Investigation 1993 68 1 33 44 2-s2.0-0027472067
12. Nelles J. L., Hu W. Y., Prins G. S., Estrogen action and prostate cancer. Expert Review of Endocrinology and Metabolism 2011 6 3 437 451 2-s2.0-79956152559 10.1586/eem.11.20
13. Ellem S. J., Schmitt J. F., Pedersen J. S., Frydenberg M., Risbridger G. P., Local aromatase expression in human prostate is altered in malignancy. Journal of Clinical Endocrinology and Metabolism 2004 89 5 2434 2441 2-s2.0-2442486485 10.1210/jc.2003-030933
14. Montgomery R. B., Mostaghel E. A., Vessella R., Hess D. L., Kalhorn T. F., Higano C. S., True L. D., Nelson P. S., Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Research 2008 68 11 4447 4454 2-s2.0-49249119358 10.1158/0008-5472.CAN-08-0249
15. Leav I., Lau K., Adams J., McNeal J., Taplin M., Wang J., Singh H., Ho S., Comparative studies of the estrogen receptors β and α and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. The American Journal of Pathology 2001 159 1 79 92 2-s2.0-0035408472
16. Leung Y.-K., Lam H.-M., Wu S., Song D., Levin L., Cheng L., Wu C.-L., Ho S.-M., Estrogen receptor β 2 and β 5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion. Endocrine-Related Cancer 2010 17 3 675 689 2-s2.0-77956363192 10.1677/ERC-09-0294
17. Linja M. J., Savinainen K. J., Tammela T. L. J., Isola J. J., Visakorpi T., Expression of ER α and ER β in prostate cancer. Prostate 2003 55 3 180 186 2-s2.0-0037738778 10.1002/pros.10242
18. Lau K.-M., LaSpina M., Long J., Ho S.-M., Expression of estrogen receptor (ER)- α and ER- β in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. Cancer Research 2000 60 12 3175 3182 2-s2.0-0034126666
19. Huggins C., Hodges C. V., Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Research 1941 1 293 297
20. Bonkhoff H., Berges R., The evolving role of oestrogens and their receptors in the development and progression of prostate cancer. European Urology 2009 55 3 533 542 2-s2.0-58849083630 10.1016/j.eururo.2008.10.035
21. Rossi V., Bellastella G., de Rosa C., Abbondanza C., Visconti D., Maione L., Chieffi P., Della Ragione F., Prezioso D., de Bellis A., Bellastella A., Sinisi A. A., Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptor α and β Journal of Cellular Physiology 2011 226 5 1334 1339 2-s2.0-79951803204 10.1002/jcp.22461
22. Rohlff C., Blagosklonny M. V., Kyle E., Kesari A., Kim I. Y., Zelner D. J., Hakim F., Trepel J., Bergan R. C., Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21(waf1/cip1). The Prostate 1998 37 1 51 59
23. Bergan R. C., Reed E., Myers C. E., Headlee D., Brawley O., Cho H.-K., Figg W. D., Tompkins A., Linehan W. M., Kohler D., Steinberg S. M., Blagosklonny M. V., A phase II study of high-dose tamoxifen in patients with hormone- refractory prostate cancer. Clinical Cancer Research 1999 5 9 2366 2373 2-s2.0-0032862225
24. Lissoni P., Vigano P., Vaghi M., Frontini L., Giuberti C., Manganini V., Casu M., Brivio F., Niespolo R., Strada G., A phase II study of tamoxifen in hormone-resistant metastatic prostate cancer: possible relation with prolactin secretion. Anticancer Research 2005 25 5 3597 3599 2-s2.0-23344437327
25. Shazer R. L., Jain A., Galkin A. V., Cinman N., Nguyen K. N., Natale R. B., Gross M., Green L., Bender L. I., Holden S., Kaplan L., Agus D. B., Raloxifene, an oestrogen-receptor- β -targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial. BJU International 2006 97 4 691 697 2-s2.0-33644895429 10.1111/j.1464-410X.2006.05974.x
26. Stein S., Zoltick B., Peacock T., Holroyde C., Haller D., Armstead B., Malkowicz S. B., Vaughn D. J., Phase II trial of toremifene in androgen-independent prostate cancer: a penn cancer clinical trials group trial. The American Journal of Clinical Oncology 2001 24 3 283 285 2-s2.0-0034989461 10.1097/00000421-200106000-00015
27. Sporn M. B., Dowsett S. A., Mershon J., Bryant H. U., Role of raloxifene in breast cancer prevention in postmenopausal women: clinical evidence and potential mechanisms of action. Clinical Therapeutics 2004 26 6 830 840 2-s2.0-3242732349 10.1016/S0149-2918(04)90127-0
28. Lim H. K., Yang M., Lam W., Xu F., Chen J., Xu Y., Shetty H. U., Yang K., Silva J., Evans D. C., Free radical metabolism of raloxifene in human liver microsomes. Xenobiotica 2012 42 737 747
29. Greish K., Nagamitsu A., Fang J., Maeda H., Copoly(styrene-maleic acid)-pirarubicin micelles: high tumor-targeting efficiency with little toxicity. Bioconjugate Chemistry 2005 16 1 230 236 2-s2.0-12344272662 10.1021/bc040297g
30. Greish K., Sawa T., Fang J., Akaike T., Maeda H., SMA-doxorubicin, a new polymeric micellar drug for effective targeting to solid tumours. Journal of Controlled Release 2004 97 2 219 230 2-s2.0-2942583635 10.1016/j.jconrel.2004. 03.027
31. Vichai V., Kirtikara K., Sulforhodamine B colorimetric assay for cytotoxicity screening. Nature Protocols 2006 1 3 1112 1116 2-s2.0-34347230544 10.1038/nprot.2006.179
32. Thorin-Trescases N., Ono Y., Tremblay J., Hamet P., Orlov S. N., Dual effect of adenosine on vascular smooth muscle [3H]-thymidine DNA labeling: receptor-mediated modulation of DNA synthesis and inhibition of thymidine uptake. Journal of Vascular Research 2000 37 6 477 484 2-s2.0-0034501245 10.1159/000054080
33. Somers-Edgar T. J., Taurin S., Larsen L., Chandramouli A., Nelson M. A., Rosengren R. J., Mechanisms for the activity of heterocyclic cyclohexanone curcumin derivatives in estrogen receptor negative human breast cancer cell lines. Investigational New Drugs 2011 29 1 87 97 2-s2.0-79151481328 10.1007/s10637-009-9339-0
34. Taurin S., Sandbo N., Qin Y., Browning D., Dulin N. O., Phosphorylation of β -catenin by cyclic AMP-dependent protein kinase. Journal of Biological Chemistry 2006 281 15 9971 9976 2-s2.0-33744519452 10.1074/jbc.M508778200
35. Friedrich J., Seidel C., Ebner R., Kunz-Schughart L. A., Spheroid-based drug screen: considerations and practical approach. Nature Protocols 2009 4 3 309 324 2-s2.0-60549103259 10.1038/nprot.2008.226
36. Taurin S., Nehoff H., Greish K., Anticancer nanomedicine and tumor vascular permeability, where is the missing link? Journal of the Controlled Release Society 2012 164 265 275
37. Moghimi S. M., Hunter A. C., Murray J. C., Long-circulating and target-specific nanoparticles: theory to practice. Pharmacological Reviews 2001 53 2 283 318 2-s2.0-0034996764
38. Nakamura H., Fang J., Gahininath B., Tsukigawa K., Maeda H., Intracellular uptake and behavior of two types zinc protoporphyrin (ZnPP) micelles, SMA-ZnPP and PEG-ZnPP as anticancer agents; unique intracellular disintegration of SMA micelles. Journal of Controlled Release 2011 155 3 367 375 2-s2.0-80054695837 10.1016/j.jconrel.2011.04.025
39. Pravettoni A., Mornati O., Martini P. G. V., Marino M., Colciago A., Celotti F., Motta M., Negri-Cesi P., Estrogen receptor beta (ERbeta) and inhibition of prostate cancer cell proliferation: studies on the possible mechanism of action in DU145 cells. Molecular and Cellular Endocrinology 2007 263 1-2 46 54 2-s2.0-34249659228 10.1016/j.mce.2006.08.008
40. Lokeshwar B. L., Selzer M. G., Block N. L., Gunja-Smith Z., Secretion of matrix metalloproteinases and their inhibitors (tissue inhibitor of metalloproteinases) by human prostate in explant cultures: reduced tissue inhibitor of metalloproteinase secretion by malignant tissues. Cancer Research 1993 53 18 4493 4498 2-s2.0-0027443276
41. Trdan Lusin T., Stieger B., Marc J., Mrhar A., Trontelj J., Zavratnik A., Ostanek B., Organic anion transporting polypeptides OATP1B1 and OATP1B3 and their genetic variants influence the pharmacokinetics and pharmacodynamics of raloxifene. Journal of Translational Medicine 2012 10, article 76 10.1186/1479-5876-10-76
42. Svoboda M., Riha J., Wlcek K., Jaeger W., Thalhammer T., Organic anion transporting polypeptides (OATPs): regulation of expression and function. Current Drug Metabolism 2011 12 2 139 153 2-s2.0-79952809873 10.2174/138920011795016863
43. Chang J. H., Kochansky C. J., Shou M., The role of P-glycoprotein in the bioactivation of raloxifene. Drug Metabolism and Disposition 2006 34 12 2073 2078 2-s2.0-33751517109 10.1124/dmd.106.012179
44. Jeong E. J., Lin H., Hu M., Disposition mechanisms of raloxifene in the human intestinal Caco-2 model. Journal of Pharmacology and Experimental Therapeutics 2004 310 1 376 385 2-s2.0-3042681890 10.1124/jpet.103.063925
45. van Brussel J. P., van Steenbrugge G. J., Romijn J. C., Schröder F. H., Mickisch G. H. J., Chemosensitivity of prostate cancer cell lines and expression of multidrug resistance-related proteins. European Journal of Cancer 1999 35 4 664 671 2-s2.0-0033119073 10.1016/S0959-8049(98)00435-3
46. Doherty G. J., McMahon H. T., Mechanisms of endocytosis. Annual Review of Biochemistry 2009 78 857 902 2-s2.0-67650711138 10.1146/annurev.biochem.78. 081307.110540
47. Zaki N. M., Tirelli N., Gateways for the intracellular access of nanocarriers: a review of receptor-mediated endocytosis mechanisms and of strategies in receptor targeting. Expert Opinion on Drug Delivery 2010 7 8 895 913 2-s2.0-77954880957 10.1517/17425247.2010.501792
48. Maeda H., Nakamura H., Fang J., The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Advanced Drug Delivery Reviews 2013 65 71 79
49. Mandlekar S., Kong A. N., Mechanisms of tamoxifen-induced apoptosis. Apoptosis 2001 6 6 469 477 2-s2.0-0035181465 10.1023/A:1012437607881
50. Obrero M., Yu D. V., Shapiro D. J., Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen- induced programmed cell death. Journal of Biological Chemistry 2002 277 47 45695 45703 2-s2.0-0037160095 10.1074/jbc.M208092200
51. Kim I. Y., Kim B.-C., Seong D. H., Lee D. K., Seo J.-M., Hong Y. J., Kim H.-T., Morton R. A., Kim S.-J., Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines. Cancer Research 2002 62 18 5365 5369 2-s2.0-0037105670
52. Price D., Stein B., Sieber P., Tutrone R., Bailen J., Goluboff E., Burzon D., Bostwick D., Steiner M., Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial. Journal of Urology 2006 176 3 965 971 2-s2.0-33746524463 10.1016/j.juro.2006.04.011
53. Zou A., Marschke K. B., Arnold K. E., Berger E. M., Fitzgerald P., Mais D. E., Allegretto E. A., Estrogen receptor β activates the human retinoic acid receptor promoter in response to tamoxifen and other estrogen receptor antagonists, but not in response to estrogen. Molecular Endocrinology 1999 13 3 418 430 2-s2.0-0032965145
54. Rimler A., Culig Z., Lupowitz Z., Zisapel N., Nuclear exclusion of the androgen receptor by melatonin. Journal of Steroid Biochemistry and Molecular Biology 2002 81 1 77 84 2-s2.0-0036068772 10.1016/S0960-0760(02)00050-X
55. Taylor S. E., Martin-Hirsch P. L., Martin F. L., Oestrogen receptor splice variants in the pathogenesis of disease. Cancer Letters 2010 288 2 133 148 2-s2.0-74849127936 10.1016/j.canlet.2009.06.017
56. El Sheikh S. S., Domin J., Abel P., Stamp G., Lalani E.-N., Phosphorylation of both EGFR and ErbB2 is a reliable predictor of prostate cancer cell proliferation in response to EGF. Neoplasia 2004 6 6 846 853 2-s2.0-11144292081 10.1593/neo.04379
57. Carrion-Salip D., Panosa C., Menendez J. A., Puig T., Oliveras G., Pandiella A., De Llorens R., Massaguer A., Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands. International Journal of Oncology 2012 41 1128 1138
58. Hirschhaeuser F., Menne H., Dittfeld C., West J., Mueller-Klieser W., Kunz-Schughart L. A., Multicellular tumor spheroids: an underestimated tool is catching up again. Journal of Biotechnology 2010 148 1 3 15 2-s2.0-77953916745 10.1016/j.jbiotec.2010.01.012
59. Attiga F. A., Fernandez P. M., Weeraratna A. T., Manyak M. J., Patierno S. R., Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Research 2000 60 16 4629 4637 2-s2.0-0034662627
60. Cubitt H. E., Houston J. B., Galetin A., Prediction of human drug clearance by multiple metabolic pathways: integration of hepatic and intestinal microsomal and cytosolic data. Drug Metabolism and Disposition 2011 39 5 864 873 2-s2.0-79955023850 10.1124/dmd.110.036566
61. Matsumura Y., Maeda H., A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Research 1986 46 12 6387 6392 2-s2.0-0022858683
62. Greish K., Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. Journal of Drug Targeting 2007 15 7-8 457 464 2-s2.0-34547653668 10.1080/10611860701539584
63. Choi H. S., Liu W., Misra P., Tanaka E., Zimmer J. P., Itty Ipe B., Bawendi M. G., Frangioni J. V., Renal clearance of quantum dots. Nature Biotechnology 2007 25 10 1165 1170 2-s2.0-35148864458 10.1038/nbt1340
64. Sarin H., Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability. Journal of Angiogenesis Research 2010 2, article 14 2-s2.0-77956162919 10.1186/2040-2384-2-14
65. Greish K., Fang J., Inutsuka T., Nagamitsu A., Maeda H., Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting. Clinical Pharmacokinetics 2003 42 13 1089 1105 2-s2.0-0242288519 10.2165/00003088-200342130-00002
66. Li X., Tian X., Zhang J., Zhao X., Chen X., Jiang Y., Wang D., Pan W., In vitro and in vivo evaluation of folate receptor-targeting amphiphilic copolymer-modified liposomes loaded with docetaxel. International Journal of Nanomedicine 2011 6 1167 1184 2-s2.0-82955183300